Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical research moves fast, and so does Medpace Holdings. Investors tracking contract backlog, net new business awards, or the founder’s periodic share sales need more than a PDF dump. This page brings every Medpace SEC filing together with context, giving you Medpace SEC filings explained simply.
Searching for the latest Medpace quarterly earnings report 10-Q filing or craving the Medpace annual report 10-K simplified? Our AI reads each document the moment it hits EDGAR, translating CRO jargon—screening rates, site-activation metrics, margin expansion—into plain English. The same engine sends alerts on Medpace insider trading Form 4 transactions, so you see leadership’s moves before the market fully reacts. A scroll-free dashboard keeps everything organized while understanding Medpace SEC documents with AI becomes effortless.
Use these tools to:
- Track Medpace Form 4 insider transactions real-time and spot buying or selling trends
- Dig into backlog changes with our Medpace earnings report filing analysis
- Decode 8-K announcements—Medpace 8-K material events explained in seconds
- Review the Medpace proxy statement executive compensation without wading through tables
- Stay current on Medpace executive stock transactions Form 4 alongside other filings
Whether you’re modelling revenue per headcount or comparing CRO margins, Stock Titan’s AI-powered summaries, expert context and real-time updates turn dense disclosures into clear, actionable knowledge.
Form 4 insider filing – Fiserv, Inc. (FI)
On 30 June 2025, director Charlotte Yarkoni elected to defer US$32,500 of board fees under Fiserv’s Non-Employee Director Deferred Compensation Plan. In exchange, she received 189 deferred-compensation notional units, calculated at the same-day closing share price of $172.41. Each unit represents the right to receive one share of Fiserv common stock after her board tenure ends.
- Transaction code: A (acquisition, non-open-market)
- Units acquired: 189
- Implied value: $32,500
- Post-transaction holdings: 1,100 notional units (direct ownership)
- Settlement: 1-for-1 share conversion upon separation
The filing reports no sales, option exercises, or other derivative activity. Because the transaction stems from fee deferral rather than discretionary share purchases, it does not signal a valuation call, yet it marginally increases equity alignment between the director and shareholders. Given Fiserv’s multibillion-dollar market capitalisation, the dollar value is immaterial to earnings or valuation models and is unlikely to affect trading sentiment. Investors may view the steady use of the deferred-fee program as normal governance practice rather than a catalyst.
Upstart Holdings, Inc. (UPST) – Form 144 insider notice
Insider Natalia Mirgorodskaya has filed to sell up to 6,533 common shares through Charles Schwab on or about 07/02/2025. At the reference price used in the filing, the transaction is valued at roughly $457,674. The shares were obtained the same day via an employee stock-option cashless exercise. Mirgorodskaya also disclosed two prior sales in the last three months—764 shares for $35,874 on 05/20/2025 and 1,340 shares for $59,215 on 05/23/2025.
With 95,144,858 shares outstanding, the proposed sale represents approximately 0.007 % of total shares, indicating a limited potential impact on the float. The filer certified that no undisclosed adverse information is known, in accordance with Rule 144 requirements.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
What is the core business of Medpace Holdings?
How does Medpace support the clinical trial process?
What industries does Medpace primarily serve?
How does Medpace ensure regulatory compliance during drug development?
What distinguishes Medpace from other clinical research organizations?
How is Medpace positioned within the global market?
What additional services does Medpace offer beyond clinical trial management?
What role do strategic partnerships play at Medpace?
